Apogenix AG
ESMO and Apogenix Collaborate on ‘Recurrent Glioblastoma Management: Challenges and Opportunities’ Colloquium
DGAP-News: Apogenix AG
/ Key word(s): Conference
ESMO and Apogenix Collaborate on “Recurrent Glioblastoma Management: Challenges and Opportunities” Colloquium Heidelberg, Germany, September 24, 2019 – Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced today that it will be supporting a colloquium titled “Recurrent Glioblastoma Management: Challenges and Opportunities” at this year’s ESMO Congress, held from September 27 to October 1 at the Fira Gran Via in Barcelona, Spain. The chairs and speakers – all international experts in the glioblastoma field – will discuss the current standard of care for recurrent glioblastoma, novel treatment approaches, the role and biological mechanisms of the CD95/CD95 ligand (Fas/Fas ligand) pathway, as well as the rationale and clinical results of CD95 ligand/Fas ligand inhibition. The colloquium will take place on Monday, September 30, 2019, from 6:30 to 8:00 pm in Hall 3, Salamanca Auditorium. – Emilie Le Rhun, M.D., Senior Neuro-Oncologist at the Department of Neurosurgery at the University Hospital Lille, France – Prof. Matthias Preusser, M.D., Head of the Division of Oncology at the Medical University of Vienna, Austria Speakers further include: – Prof. Michael Weller, M.D., Director of the Department of Neurology at the University Hospital Zurich, Switzerland – Prof. Wolfgang Wick, M.D., Medical Director and Chairman of the Neurology Clinic at the Heidelberg University Hospital, Germany About Apogenix About Asunercept
24.09.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |